Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

China

Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Heath Hoglund talks about the value proposition of patent pools and why it went ahead with its first-ever series of pool meetings in China
Sponsored

Sponsored

  • Sponsored by Beijing Kangrui Law Firm
    Echo Xu of Kangxin examines a number of cases which consider whether original equipment manufacturers are “using” a trademark when they affix it to a product which will be exported from China
  • Sponsored by Panawell & Partners
    Paula Pei of Panawell discusses the need to register a Chinese language mark, the different ways to choose a Chinese language mark and the challenges businesses may face when registering such marks
  • Sponsored by Vivien Chan & Co
    Vivien Chan and Ann Xu of Vivien Chan & Co. analyse the Anti-Unfair Competition Law and its impact on IP cases in China
  • Sponsored by Wanhuida Intellectual Property
    Paul Ranjard and Zhu Zhigang of Wanhuida examine the different cases selected by the Supreme Court in 2019, including those involving position trademarks, OEM processes, and prior use
  • Sponsored by GoldenGate Lawyers
    Attempting to establish a trademark infringement test, on December 18 2019, the China National Intellectual Property Administration (CNIPA) released draft Criteria for Determining Trademark Infringement (Consultation Draft), inviting public comments.
  • Sponsored by AnJie Law Firm
    In the US-China Phase One trade deal signed on January 15 2020, notable agreements on patents mostly relate to pharmaceutical sectors – Articles 1.10, 1.11 and 1.12. It is possible that these articles may also have implications for other sectors, which remains to be seen in the subsequent implementation. In addition, the provisions on judicial enforcement and procedures should benefit all patent owners. More technical issues such as indirect infringement or changes to the judicial review of invalidation decisions are not addressed. This update provides a brief overview of these key changes.